GelStat Corp. (GSAC)
OTCMKTS · Delayed Price · Currency is USD
0.0004
-0.0001 (-12.50%)
Oct 31, 2025, 4:00 PM EDT
GelStat Revenue
GelStat had revenue of $80.08K in the quarter ending June 30, 2025, with 2.77% growth. This brings the company's revenue in the last twelve months to $363.53K, up 71.17% year-over-year. In the year 2024, GelStat had annual revenue of $349.73K with 133.89% growth.
Revenue (ttm)
363.53K
Revenue Growth
+71.17%
P/S Ratio
3.60
Revenue / Employee
181.77K
Employees
2
Market Cap
1.31M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 349.73K | 200.20K | 133.89% |
| Dec 31, 2023 | 149.53K | 147.19K | 6,309.22% |
| Dec 31, 2022 | 2.33K | -4.69K | -66.78% |
| Dec 31, 2021 | 7.02K | 3.07K | 77.77% |
| Dec 31, 2020 | 3.95K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| China New Energy Group Co. | 12.51M |
| Northwest Biotherapeutics | 1.09M |
GelStat News
- 5 months ago - GSAC Engineering Secures Multi-Year Recurring Revenue Contract - GlobeNewsWire
- 2 years ago - GSAC Engineering Acquires Key Intellectual Property and Assets from Duos Technologies Group - GlobeNewsWire
- 2 years ago - GelStat Forms New and Advanced Engineering Division - GlobeNewsWire
- 3 years ago - GelStat Provides Corporate Update on Capital Restructuring - GlobeNewsWire